p73: Friend or foe in tumorigenesis

Nature Reviews Cancer

Volumn 2, Issue 8, 2002, Pages 605-615

  Melino, Gerry ^a   De Laurenzi, Vincenzo ^a   Vousden, Karen H ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; PROTEIN; PROTEIN DELTA NP73; PROTEIN P53; PROTEIN P73; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; CANCER GENETICS; CANCER INHIBITION; CARCINOGENESIS; DNA DAMAGE; GENE FUNCTION; GENETIC CODE; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; TRANSACTIVATION; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; MUTATION; NEOPLASM; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 0036674502     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc861     Document Type: Review

References (135)

1. Yang, A. & McKeon, F. p63 and p73: p53 mimics, menace and more. Nature Rev. Mal. Cell. Biol. 1, 199-207 (2000).
2. Yang, A., Kaghad, M., Caput, D. & McKeon, F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18, 90-95 (2002).
3. Irwin, M. S. & Kaelin, W. G. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ. 12, 337-349 (2001).
4. Levrero, M. et al. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci. Cell Sci. 113, 1661-1670 (2000).
5. Derry, W. B., Putzke, A. P. & Rothman, J. H. Caenorhabditis elegans p53: role in apoptosis, meiosis, and stress resistance. Science 294, 591-595 (2001). Cloning of the p53 orthologue in Caenorhabditis elegans, providing evidence for its involvement in apoptosis following ionizing irradiation, as well as in meiosis.
6. Brodsky, M. H. et al. Drosophila p53 binds a damage response element at the reaper locus. Cell 101, 103-113 (2000).
7. Ollmann, M. et al. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell 101, 91-101 (2000). References 6 and 7 describe the cloning of the p53 orthologue in Drosophila melanogaster.
8. Kaghad, M. et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809-819 (1997). First description and cloning of p73.
9. De Laurenzi, V. et al. Two new p73 splice variants, γ and δ, with different transcriptional activity. J. Exp. Med 188, 1763-1768 (1998). Description of the p73 splicing isoforms and their function.
10. De Laurenzi, V. et al. Additional complexity in p73: induction by mitogens in lymphold cells and identification of two new splicing variants ε and ζ. Cell Death Differ. 6, 389-390 (1999).
11. Kong, X. et al. Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines. Neoplasia 1, 80-89 (2000).
12. Ueda, Y., Hijikata, M., Takagi, S., Chiba, T. & Shimotohno, K. New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 18, 4993-4998 (1999).
13. Ueda, Y., Hijikata, M., Takagi, S., Chiba, T. & Shimotohno, K. Transcriptional activities of p73 splicing variants are regulated by inter-variant association. Biochem. J. 356, 859-866(2001).
14. Ishimoto, O. et al. Possible oncogenic potential of δNp73: a newly identified isoform of human p73. Cancer Res, 62, 636-664 (2002).
15. Tnanos, C. D. & Bowie, J. U. p53 family members, p63 and p73, are SAM domain-containing proteins. Protein Sci. 8, 1706-1710 (1999).
16. Chi, S.-W., Ayed, A. & Arrowsmith, C. H. Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J. 18, 4438-4445 (1999).
17. Arrowsmith, C. H. Structure and function in the p53 family. Cell Death Differ. 6, 1169-1173 (1999).
18. Jousset, C. et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFRβ oncoprotein. EMBO J. 16, 69-82 (1997).
19. Kyba, M. & Brock, H. W. The SAM domain of polyhomeotic, RAE28, and scm mediates specific interactions through conserved residues. Dev. Genet. 22, 74-84 (1998).
20. Schultz, J., Ponting, C. P., Hofmann, K. & Bork, P. SAM as a protein interaction domain involved in developmental regulation. Protein Sci. 6, 249-253 (1997).
21. Thanos, C. D., Goodwill, K. E. & Bowie, J. U. Oligomeric structure of the human EphB2 receptor SAM domain. Science 283, 833-836 (1999).
22. Jost, C. A., Marin, M. C. & Kaelin, W. G. p73 is a simian p53-related protein that can induce apoptosis. Nature 389, 191-194 (1997).
23. Yang, A. et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404, 99-103 (2000). Report of the knockout mouse for p73, describing neural and infective abnormalities.
24. Pozniak, C. D. et al. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289, 304-306 (2000). Reports the ability of ΔNp73 to protect from NGF-withdrawal-induced apoptosis in embryonic neurons.
25. Grob, T. J. et al. Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8, 1213-1223 (2001). Cloning of the human ΔNp73 isoforms and the ΔNp73 promoters and description of the ΔNp73 dominant-negative loop on TAp73 and p53.
26. Stiewe, T., Theseling, C. C. & Putzer, B. M. Transactivation-deficient ΔTA-p73 inhibits p53 by direct competition for DNA-binding: implications for tumorigenesis J. Biol. Chem. 13 Feb 2002 [epub ahead of print].
27. Fillippovich, I. et al. Transactivation-deficient p73α (p73Δ exon 2) inhibits apoptosis and competes with p53. Oncogene 20, 514-522 (2001). Description and characterization of the Δ2p73 splicing isoform in cancer.
28. Nakagawa, T. et al. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Mol. Cell. Biol. 22, 2575-2585 (2002).
29. Vossio, S. et al. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest. Oncogene 21, 3796-3803 (2002).
30. Kartasheva, N. N., Contente, A., Lenz-Sẗppler, C., Roth, J. & Dobbelstein, M. p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop. Oncogene (in the press).
31. Stiewe, T., Zimmermann, S., Frilling, A., Esche, H. & Puetzer, B. M. Transactivation-deficient DTA-p73 acts as an oncogene. Cancer Res. (in the press).
32. Allart, S. et al. Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of ΔN p73α. J. Biol. Chem. 28 May 2002 [epub ahead of print].
33. Jones, S. N., Roe, A. E., Donehower, L. A. & Bradley, A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 Nature 378, 206-208 (1995).
34. Parant, J. et al. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genet. 29, 92-95 (2001).
35. Gong, J. C. et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399, 806-809 (1999).
36. Agami, R., Blandino, G., Oren, M. & Shaul, Y. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature 399, 809-813 (1999).
37. Yuan, Z. M. et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399, 814-817 (1999). References 35-37 describe the MLH1-c-Abl-p73 pathway in DNA damage.
38. Catani, M. V. et al. Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: implications for the cellular response to DNA damage. Biochem. J. 364, 441-447 (2002).
39. Sanchez-Prieto, R., Sanchez-Arevalo, V. J., Servitja, J.-M. & Gutkind, S. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 21, 974-979 (2002).
40. Kim, E. J., Park, J. S. & Um, S. J. Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo J. Biol. Chem. 29 Mar 2002 [epub ahead of print].
41. Costanzo, A. et al. DNA damage-dependent acetylation dictates the selective activation of apoptotic target genes. Mol. Cell 9, 175-186 (2002). Acetylation determines whether p73 binds to apoptotic or cell-cycle promoters.
42. Prives, C. & Manley, J. L. Why is p53 acetylated? Cell 107, 815-818 (2001).
43. Stiewe, T. & Putzer, B. M. Role of the p53 homologue p73 in E2F1-induced apoptosis, Nature Genet. 26, 464-469 (2000).
44. Lissy, N. A., Davis, P. K., Irwin, M., Kaelin, W. G. & Dowdy, S. F. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 407, 642-645 (2000).
45. Irwin, M. et al. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407, 645-648 (2000).
46. Leone, G. et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol. Cell. 8, 105-113 (2001).
47. Zaika, A., Irwin, M., Sansome, C. & Moll, U. M. Oncogenes induce and activate endogenous p73 protein. J. Biol. Chem. 276, 11310-11316 (2001).
48. Watanabe, K. K. et al. Physical interaction of p73 with c-Myc and MM1. a c-Myc-binding protein, and modulation of the p73. J. Biol. Chem. 13 Feb 2002 [epub ahead of print].
49. Balint, E., Bates, S. & Vousden, K. H. Mdm2 binds p73α without targeting degradation. Oncogene 18, 3923-3929 (1999).
50. Lee, C. W. & La Thangue, N. B. Promoter specificity and stability control of the p53-related protein p73. Oncogene 18, 4171-4181 (1999).
51. Dobbelstein, M., Wienzek, S., Konig, C. & Roth, J. Inactivation of the p53 homologue p73 by the Mdm2 oncoprotein. Oncogene 18, 2101-2106 (1999).
52. Ongkeko, W. et al. MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr. Biol. 9, 829-832 (1999).
53. Zeng, X. et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19, 3257-3266 (1999).
54. Wang, X. Q. et al. Mdm2 and MdmX can interact differently with ARF and members of the p53 family. FEBS Lett. 490, 202-208 (2001).
55. Wang, X. Q., Ongkeko, W. M., Lau, A. W. S., Leung, K. M. & Poon, R. Y. C. A possible role of p73 on the modulation of p53 level through Mdm2. Cancer Res. 61, 1598-1603 (2001).
56. Zeng, X. et al. The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. Mol. Cell. Biol. 20, 1299-1310 (2000).
57. Lohrum, M. A., Woods, D. B., Ludwig, R. L., Balint, E. & Vousden, K. H. C-terminal ubiquitination of p53 contributes to nuclear export Mol. Cell. Biol. 21, 8521-8532 (2001).
58. Gu, J., Nie, L., Kawai, H. & Yuan, Z. M. Subcellular distribution of p53 and p73 are differentially regulated by MDM2. Cancer Res. 61, 6703-6707 (2001).
59. Minty, A., Dumont, X., Kaghad, M. & Caput, D. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J. Biol. Chem. 275, 36316-36323 (2000).
60. Scharnhorst, V., Dekker, P., van Der Eb, A. J. & Jochemsen, A. G. Physical interaction between Wilms' tumour 1 and p73 proteins modulates their functions. J. Biol. Chem. 275, 10202-10211 (2000).
61. Flores, E. R. et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564 (2002). Evidence that p53 requires the presence of either p63 or p73 to induce apoptosis; p73/p63 drive p53 towards apoptotic promoters such as NOX4, PERP and BAX.
62. Steengenga, W. T., Shvarts, A., Riteco, N., Bos, J. L. & Jochemsen, A. G. Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and E4orf6 proteins, Mol. Cell. Biol. 19, 3885-3894 (1999).
63. Kaida, A. et al. Functional impariment of p73 and p51, the p53-related proteins, by the human T-cell leukaemia virus type 1 Tax oncoprotein. Oncogene 19, 827-830 (2000).
64. Marin, M. C. et al. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol. Cell. Biol. 18, 6316-6324 (1998).
65. Prabhu, N., Somasundaram, K., Satyamoorthy, K., Herlyn, M. & El-Deiry, W. p73β, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int. J. Oncol. 13, 5-9 (1998).
66. Dobbelstein, M. & Roth, J. The large T antigen of simian virus 40 binds and inactivates p53 but not p73. J. Gen. Virol. 79, 3079-3083 (1998).
67. Roth, J. et al. Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins. J. Virol. 72, 8510-8516 (1998).
68. Higashino, F., Pipas, J. M. & Shenk, T. Adenovirus E4orf6 oncoprotein modulates the function of the p53-related protein, p73. Proc. Natl Acad. Sci. USA 95, 15683-15687 (1998).
69. De Laurenzi, V. et al. Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J. Biol. Chem. 275, 15226-15231 (2000). First report of the involvement of p73 in neural differentiation.
70. De Laurenzi, V. et al. p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem. Biophys. Res. Commun. 273, 342-346 (2000).
71. Yu, J. et al. Identification and classification of p53-regulated genes. Proc. Natl Acad. Sci. USA 96, 14517-14522 (1999).
72. Zhu, J., Jiang, J., Zhou, W. & Chen, X. The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58, 5061-5065 (1998).
73. Ueda, Y. et al. p73β, a variant of p73, enhances Wnt/β-catenin signaling in Saos-2 cells. Biochem. Biophys. Res. Commun. 283, 327-333 (2001).
74. Takagi, S., Ueda, Y., Hijikata, M. & Shimotohno, K. Overproduced p73α activates a minimal promoter through a mechanism independent of its transcriptional activity. FEBS Lett. 509, 7-52 (2001).
75. Balint, E., Phillips, A. C., Kozlov, S., Stewart, C. L. & Vousden, K. H. Induction of p57KIP2 expression by p73β. Proc. Natl Acad. Sci. USA 99, 3529-3534 (2002).
76. Ikawa, S., Nakagawara, A. & Ikawa, Y. p53 family genes: structural comparison, expression and mutation Cell Death Differ. 6, 1154-1161 (1999).
77. Ng, S. W. et al. Analysis of p73 in human borderline and invasive ovarian tumour. Oncogene 19, 1855-1890 (2000).
78. O'Nions, J. et al. p73 is over-expressed in vulval cancer principally as the Δ2 isoform. Br. J. Cancer 85, 1551-1556 (2001).
79. Douc-Rasy, S. et al. DNp73a accumulates in human neuroblastic tumours. Am. J. Pathol. 160, 631-636 (2002).
80. Casciano, I. et al. Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9, 246-251 (2002). Correlation of ΔNp73 with adverse prognosis in neuroblastoma patients, with ten years of follow-up.
81. Casciano, I. et al. Role of methylation in the control of ΔNp73 expression in neuroblastoma. Cell Death Differ. 9, 343-345 (2002).
82. DiComo, C. J., Gaiddon, C. & Prives, C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19, 1438-1449 (1999).
83. Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T. & Prives. C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21, 1874-1887 (2001).
84. Strano, S. et al. Physical and functional interaction between p53 mutants and different isoforms of p73 J. Biol. Chem. 275, 29503-29512 (2000).
85. Mann, M. C. et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nature Genet. 25, 47-54 (2000).
86. Ryan, B. M. et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br. J. Cancer 85, 1499-1503 (2001).
87. Kawano, S. et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94, 1113-1120 (1999).
88. Corn, P. G. et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′CpG island methylation, Cancer Res. 59, 3352-3356 (1999).
89. Yang, A. et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714-718 (1999).
90. Mills, A. A. et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398, 708-713 (1999).
91. Brodeur, G. M. Molecular basis for heterogeneity in human neuroblastoma. Eur. J. Cancer 31A, 505-510 (1995).
92. Lasorella, A., Noseda, M., Beyna, M. & Iavarone, A. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407, 592-598 (2000).
93. Kitanaka, C. et al. Increased Ras expression and caspase-independent neuroblastoma cell death: possible mechanism of spontaneous neuroblastoma regression. J. Natl Cancer Inst. 94, 358-368 (2002).
94. Kovalev, S., Marchenko, N., Swendeman, S., LaQuaglia, M. & Moll, U. M. Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ. 9, 897-903 (1998).
95. Ichimiya, S. et al. p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 18, 1061-1066 (1999).
96. Ejeskar, K., Sjoberg, R. M., Kogner, P. & Martinsson, T. Variable expression and absence of mutations in p73 in primary neuroblastoma tumors argues against a role in neuroblastoma development. Int. J. Mol. Med. 3, 585-589 (1999).
97. Han, S. et al. Infrequent somatic mutations of the p73 gene in various human cancers. Eur. J. Surg. Oncol. 25, 194-198 (1999).
98. Liu, W. et al. Differential expression and allelotyping of the p73 gene in neuroblastoma. Int. J. Oncol. 16, 181-185 (2000).
99. Yang, H. W. et al. The p73 gene is less involved in the development but involved in the progression of neuroblastoma. Int. J. Mol. Med. 5, 379-384 (2000).
100. Kong, X. T. et al. Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines. Neoplasia 1, 80-89 (1999).
101. Chi, S.-G. et al. Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res. 59, 2791-2793 (1999).
102. Lomas, J. et al. Analysis of p73 gene in meningiomas with deletion at 1p. Cancer Genet. Cytogenet. 129, 88-91 (2001).
103. Nozaki, M. et al. p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade. Brain Pathol. 11, 296-305 (2001).
104. Alonso, M. E. et al. Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br. J. Cancer 85, 204-208 (2001).
105. Kroiss, M. M. et al. Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. Melanoma Res. 8, 504-509 (1998).
106. Herbst, R. A. et al. Allelic loss at the p73 locus (1p36.33) is infrequent in malignant melanoma. Arch. Dermatol. Res. 291, 362-364 (1999).
107. Schittek, B., Sauer B. & Garbe, C. Lack of p73 mutations and late occurrence of p73 allelic deletions in melanoma tissues and cell lines. Int. J. Cancer 82, 583-586 (1999).
108. Shan, L. et al. Frequent loss of heterozygosity at 1 p36.3 and p73 abnormality in parathyroid adenomas. Mod. Pathol. 14, 273-278 (2001).
109. Nomoto, S. et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 58, 1380-1383 (1998).
110. Nicholson, S. A. et al. Alterations of pl 4ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res. 61, 5636-5643 (2001).
111. Ma, M. et al. Activation of p73 silent allele in lung cancer. Cancer Res. 58, 2347-2349 (1998).
112. Tokuchi, Y. et al. The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br. J. Cancer 80, 1623-1629 (1999).
113. Faridoni-Laurens, L. et al. p73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63? Oncogene 20, 5302-5312 (2001).
114. Nimura, Y. et al. p73, a gene related to p53, is not mutated in esophageal carcinomas. Int. J. Cancer 78, 437-440 (1998).
115. Cal, Y. C. et al. Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis 21, 683-689 (2000).
116. Kang, M. J. et al. Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma Clin. Cancer Res. 6, 1767-1771 (2000).
117. Yokozaki, H. et al. Aterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. Int. J. Cancer 83, 192-196 (1999).
118. Sunahara, M. et al. Mutational analysis of the p73 gene localized at chromosome 1p36.3 in colorectal carcinomas. Int. J. Oncol. 13, 319-323 (1998).
119. Yokomizo, A. et al. Mutation and expression analysis of the p73 gene in prostate cancer. Prostate 39, 94-100 (1999).
120. Takahashi, H. et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 58, 2076-2077 (1998).
121. Mai, M. et al. Loss of imprinting and allele switching of p73 in renal cell carcinoma. Oncogene 17, 1730-1741 (1998).
122. Momoi, H. et al. Comprehensive allelotyping of human intrahepatic cholangiocarcinoma. Clin. Cancer Res. 7, 2646-2655 (2001).
123. Mihara, M. et al. Absence of mutation of the p73 gene localized at chromosome 1p36.3 in hepatocellular carcinoma. Br. J. Cancer 79, 164-167 (1999).
124. Peng, C. Y. et al. Genetic alternations of p73 are infrequent but may occur in early stage hepatocellular carcinoma. Anticancer Res. 20, 1487-1492 (2000).
125. Herath, N. I. et al. p73 is up-regulated in a subset of hepatocellular carcinomas. Hepatology 31, 601-605 (2000).
126. Stirewalt, D. L., Clurman, B., Appelbaum, F. R., Willman, C. L. & Radich, J. P. p73 mutations and expression in adult de novo acute myelogenous leukemia, Leukemia 13, 985-990 (1999).
127. Zaika, A. I., Kovalev, S., Marchenko, N. D. & Moll, U. M. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 59, 3257-3263 (1999).
128. Shishikura, T. et al. Mutational analysis of the p73 gene in human breast cancers. Int. J. Cancer 84, 321-325 (1999).
129. Schwartz, D. I. et al. p73 mutations are not detected in sporadic and hereditary breast cancer. Breast Cancer Res. Treat. 58, 25-29 (1999).
130. Dominguez, G. et al. Clinicopathological characteristics of breast carcinomas with allelic loss in the p73 region. Breast Cancer Res. Treat. 63, 17-22 (2000).
131. Dominguez, G. et al. Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res. Treat. 66, 183-190 (2001).
132. Ahomadegbe, J. C. et al. Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. Oncogene 19, 5413-5418 (2000).
133. Chen, C. L., Ip, S. M., Cheng, D., Wong, L. C. & Ngan, H. Y. p73 gene expression in ovarian cancer tissues and cell lines. Clin. Cancer Res. 6, 3910-3915 (2000).
134. Codegoni, A. M., Bertoni, F., Patregnani, C., Marinetti, E., D'Incalci, M. & Broggini, M. Allelic expression of p73 in human ovarian cancers. Ann. Oncol. 10, 949-953 (1999).
135. Imyanitov, E. N. et al. Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene 18, 4640-4642 (1999).